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Abstract--Using a panel of four human colorectal tumor (HCT) cell lines, we have quantitatively 
characterized the incorporation of bromodeoxyuridine (BrdUrd) and iododeoxyuridine (IdUrd) into 
DNA, both as individual agents and in combination with fluoropyrimidines. The intrinsic ability of 
these cell lines to incorporate BrdUrd, as reflected by the concentration required to achieve half- 
maximal incorporation, varied almost 4-fold across this panel, from 1.6/,M for HuTu80 cells to 6.1 MM 
for HT29 cells. Three of the four cell lines (HT29, SW480, SW620) responded to fluoropyrimidines as 
expected, displaying 100-150% increases in BrdUrd incorporation when combined with growth 
inhibitory concentrations of fluorouracil (FUra). In contrast, neither FUra nor fluorodeoxyuridine 
(FdUrd) was able to increase BrdUrd incorporation in HuTu80 cells by more than 25%, even in the 
presence of 100/uM leucovorin. IdUrd incorporation was modulated to a substantially higher degree in 
both HT29 and HuTu80 cell lines. Finally we demonstrate the feasibility of a technique for evaluating 
the net effect of fluoropyrimidine treatments on de novo thymidine nucleotide production in a single 
specimen, using a combination of normotopic and stable-isotope labeled BrdUrd. We propose that this 
approach may be useful in evaluating the response of an individual tumor to fluoropyrimidines in vivo. 
Tumors of colorectal origin are among the most 
common to afflict the general adult population. 
While treatment of this type of tumor has become 
increasingly effective, employing combinations of 
surgery, radiation and chemotherapy (chiefly anti- 
metabolites), a significant portion of these tumors 
respond poorly to therapeutic treatments. Although 
no single determinant of clinical responsiveness has 
been identified as a result of these investigations, it 
has become evident that a great deal of heterogeneity 
exists among human colorectal tumors with regard 
to both their metabolism of fluoropyrimidines and 
their apparent sensitivity to the major biochemical 
lesions induced by these agents [i.e. inhibition of 
thymidine (dThd§) nucleotide synthesis and analog 
incorporation into R N A  and DNA] [see, for 
example, Refs. 1 and 2]. 
Our efforts to improve the response rate of 
colorectal tumors have recently concerned the 
use of other halopyrimidines, bromodeoxyuridine 
(BrdUrd) and iododeoxyuridine (IdUrd),  whose 
incorporation into cellular D N A  is known to sensitize 
cells to UV and X-irradiation [3]. Since these analogs 
compete with dThd for incorporation into DNA,  
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it is predictable that inhibition of endogenous 
thymidylate synthesis by fluorouracil (FUra) or 
fluorodeoxyuridine (FdUrd) should enhance their 
incorporation and, therefore, their efficacy as 
radiosensitizers. Based on this interaction, Phase I /  
II clinical trials are in progress in which either 
BrdUrd or IdUrd is combined with FUra  for the 
purpose of potentiating incorporation of the 
thymidine analogs. However, in light of the above- 
mentioned heterogeneity, it would be expected that 
the effectiveness of modulating BrdUrd or IdUrd 
incorporation with fluoropyrimidines may vary 
considerably among human colorectal tumor cell 
lines. Since addition of a fluoropyrimidine to a 
BrdUrd or IdUrd regimen potentially poses an 
increased hazard, it would be useful to quantitatively 
characterize the benefit derived (i.e. increased 
incorporation) under conditions approximating those 
expected to be operative in vivo. Therefore, we 
have performed the present study, using human 
colorectal tumor cell lines which have been shown 
previously to have widely divergent responses to 
fluoropyrimidines [4-6], to assess the relationship 
between intrinsic ability to incorporate BrdUrd into 
DNA and the modulation of this process by 
fluoropyrimidines. 
MATERIALS AND METHODS 
Cell culture and drug treatments. All cell lines were 
purchased from the American Type Culture 
Collection and maintained at 37 ° in a 5% CO2 
atmosphere, in McCoy's 5A medium supplemented 
with 10% fetal bovine serum (both from GIBCO).  
Undialyzed serum was used except where indicated. 
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Table 1. Halopyrimidine incorporation parameters for human colorectal tumor cell lines 
BrdUrd IdUrd 
Cell line Im~ (%) C~ (/aM) Ct0 (/aM) Imax (%) C50 (/aM) C,0 (/aM) 
HuTu80 36.4 ± 1.3 (4) 1.6 ± 0.2 (4) 0.18 37.2 (2) 7.5 (2) 0.8 
SW480 50.7 ± 0.8 (4) 3.6 --- 0.9 (4) 0.39 
SW620 47.8 ± 0.8 (3) 4.6 --- 0.3 (3) 0.51 
HT29 48.0 ± 1.2 (5) 6.1 --- 0.9 (5) 0.68 49.8 --- 0.4 (3) 27.1 ± 0.7 (3) 3.0 
Cells were exposed to a series of BrdUrd/IdUrd concentrations for one doubling time after which the 
extent of replacement of dThd was measured by GC/MS. Data were fitted to the equation: 1 = 
(C'lmax)/(C 3r /max), as described previously [9]. From the resulting fit we calculated -the concentrations at 
which 10 or 50% of maximal incorporation would be expected (C10 or C50), and the percent replacement 
was projected at infinitely high BrdUrd or IdUrd concentration (/max). Values are means -+ SEM (N) or 
an average of two determinations. The C10 values were calculated from the mean values for/max and C50. 
The doubling time for HT29, SW480 and SW620 
cells was typically 24 hr, while for HuTu80 cells it 
was 16 hr. Cultures were screened for mycoplasma 
contamination approximately every 3 months. 
Stable-isotope labeled BrdUrd [1,3,-15N,2-13C], 
~> 99% pure by mass spectrometric analysis, was 
custom synthesized by MSD Isotopes, Montreal, 
Canada. All other drugs and reagents were purchased 
from Sigma Biochemicals. For incorporation experi- 
a ments, cells were plated at 20,000/cm and allowed 
to recover for two doubling times before treatment. 
Analysis of BrdUrd and IdUrd incorporation. 
These determinations were performed as described 
previously [7, 8]. Briefly, cells were lysed in a buffer 
containing sodium dodecyl sulfate, followed by 
proteinase and RNase digestion and precipitation of 
cellular DNA with ethanol. Enzymatic hydrolysis 
with DNase I, phosphodiesterase, alkaline phos- 
phatase and thymidine phosphorylase liberated 
incorporated 5-bromouracil and thymine. After 
addition of 5-chlorouracil as an internal standard, 
the bases were then extracted into ethyl acetate and 
derivatized with b/s-trimethylsilyl trifluoroace- 
tamide. Quantitation of the derivatized products was 
carried out using a Hewlett-Packard 5987A gas 
chromatograph/mass spectrometer in selected ion 
monitoring mode. Initial experiments showed that 
standard curves for isotopic and normotopic BrdUrd 
were indistinguishable; therefore, a standard curve 
for only normotopic BrdUrd was constructed and 
used for both BrdUrd species. 
Measurement of growth inhibition. Cells were 
seeded in 24-well plates at a density of 20,000/cm 2 
(except for HuTu80, 7500/cm 2) and were allowed to 
recover for 2 days, after which their medium was 
replaced with medium containing FdUrd. After 
approximately 3-4 doubling times, cells were 
harvested and counted using a Coulter Counter. Cell 
growth was calculated by subtracting the number of 
cells present at the beginning of drug treatment from 
the final number. All treatments were performed in 
triplicate, using dialyzed serum. 
RESULTS 
Quantitative analysis of BrdUrd/IdUrd incor- 
poration without modulation. Previous studies from 
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Fig. 1. Incorporation in HCT cell lines at low BrdUrd 
concentrations. Cells were plated at 20,000/cm 2, allowed 
to recover for two doubling times, and then exposed to the 
indicated concentrations of BrdUrd for one doubling time. 
Incorporation of BrdUrd was measured by GC/MS analysis 
and the data presented are mean values --- SEM for 
triplicate samples from a single, representative experiment. 
our group have indicated that the quantitative 
relationship between external concentrations of 
halogenated dThd analogs and the consequent extent 
of their incorporation into DNA in place of dThd 
can be closely fit to a Langmuir equation [9]. The 
parameters derived from such a fit (C50 and/max) are 
indicative of the concentration-dependence and the 
maximum possible efficiency, respectively, of the 
overall incorporation process. Table 1 gives values 
observed for these parameters in four HCT cell lines 
for BrdUrd and two lines for IdUrd; in addition, 
values were calculated for the concentration expected 
to give 10% maximal incorporation in each instance 
(C10). Also, the actual values for incorporation at 
low BrdUrd concentrations are shown in Fig. 1. 
While the values for incorporation for these cell 
lines tend to converge at 10#M and above (not 
shown), these data demonstrate that in the clinically 
relevant (low micromolar) range, the intrinsic ability 
of HCT cell lines to incorporate BrdUrd is quite 
variable. 
Modulation of BrdUrd/IdUrd incorporation by 
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Fig. 2. Modulation of BrdUrd incorporation by FUra in a 
panel of HCT cell lines. Cells were exposed to the C10 
concentration of BrdUrd (see Table 1) plus the indicated 
concentration of FUra for one doubling time. The results 
are expressed as percent change of each FUra-treated 
sample compared to the mean incorporation of the samples 
exposed to BrdUrd only. The data presented are mean 
values --- SEM for triplicate samples from a single, 
representative experiment. Control values for percent 
replacement by BrdUrd in these experiments were: 
HuTu80, 4.7; SW480, 3.4; SW620, 3.3; and HT29, 6.2. 
FUra/FdUrd. Our initial assessment of modulation 
was performed by treating cells with the Ct0 
concentration of BrdUrd for one doubling time, in 
combination with various FUra  concentrations (Fig. 
2). Although the qualitative result that FUra 
generally enhanced BrdUrd incorporation was 
expected, the quantitative profile of this effect was 
puzzling in some respects. Several aspects of 
the response of HT29 and HuTu80 cells to 
fluoropyrimidines were characterized previously by 
Washtien [4, 5] and, based on these results, we had 
predicted that modulation of BrdUrd incorporation 
should be significant in the HT29 cells at about 1 #M 
FUra and in the HuTu80 cells at about 10 #M FUra. 
While the HT29 cells responded as expected, BrdUrd 
incorporation in the HuTu80 cells was not affected 
by 10#M FUra,  even though this concentration 
reportedly was sufficient to titrate all of the 
thymidylate synthase (TS) in this line [4]. Also, the 
finding that 100 #M FUra  produced less modulation 
than 10#M FUra  in HT29 cells was initially 
unexpected. This result, which was reproducible 
obtained in several experiments, may be due to 
growth inhibition caused by FUra  incorporation into 
RNA. 
To further characterize the differences in modu- 
lation between HT29 and HuTu80 cells, we next 
determined the dependence of modulation on 
BrdUrd concentration. As illustrated in Fig. 3, 
relative increases in BrdUrd incorporation observed 
using the C50 concentration for BrdUrd were similar 
to those seen at the Cz0 concentration in each cell 
line. This was the case when either 100 gM FUra  or 
100 nM FdUrd was used as the modulating agent. 
Since it is now well known that reduced folate 
cofactors are, in some cases, the limiting factor in 
determining the extent of TS inhibition by 
fluorodeoxyuridine monophosphate,  we repeated 
the experiments shown in Fig. 3 with the addition 
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Fig. 3. Effect of BrdUrd concentration on modulation by 
FUra or FdUrd. HT29 or HuTu80 cells were exposed to 
either the C10 or (?5o BrdUrd concentration plus 100 #M 
FUra or 100 nM FdUrd (or no fluoropyrimidine) for one- 
half of a doubling time. Values are means --- SEM for the 
percent replacement of dThd by BrdUrd (i.e. BrdUrd 
incorporation). These data are from a single, representative 
experiment (using dialyzed serum) in which triplicate 
samples were processed. 
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Fig. 4. Modulation of IdUrd incorporation by FUra. 
Modulation of IdUrd incorporation by FUra in HT29 and 
HuTu80 cells was measured as in Fig. 2 for BrdUrd. 
Control values for percent replacement by IdUrd in these 
experiments were: HuTu80, 4.4; and I-IT29, 4.5. Values 
are means -+ SEM for triplicate samples from a single 
representative experiment. 
of 100wM leucovorin. The values observed for 
incorporation were virtually identical in the absence 
or presence of leucovorin, (data not shown). 
Modulation of IdUrd incorporation by FUra  was 
studied in HT29 and HuTu80 cells, at the C10 
concentrations defined in Table 1. In both cell lines, 
IdUrd incorporation was enhanced to a substantially 
higher degree than that of BrdUrd (Fig. 4), although 
the effect in the HuTu80 line was still much less 
than in HI29  cells. Perhaps the most striking 
difference between the two analogs is the contrast 
in HuTu80 cells of the effect of 10 #M FUra/BrdUrd ,  
which produced no modulation, compared to 10 #M 
FUra / IdUrd ,  where the fluoropyrimidine doubled 
analog incorporation. 
Growth inhibition by FdUrd. Although FdUrd-  
induced growth inhibition for three of the lines used 
here was studied by Washtien [5], the modulation 
patterns we observed induced us to reexamine this 
effect. While the responses of the HT29 and SW480 
cells in our hands were virtually identical to those 
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Fig. 5. Growth inhibition of HCT cell lines by FdUrd. 
Cells were plated onto 24-well dishes and allowed to 
recover for 2 days, at which time their medium was replaced 
with FdUrd-containing medium. Growth inhibition was 
determined after 3-4 doubling times. Values are the means 
- SEM for three separate experiments. 
reported earlier (Fig. 5), the HuTu80 line was slightly 
different in that, even at 300 nM FdUrd these ceils 
grew at 20% of control rate. 
Measurement of modulation using stable-isotope 
labeled BrdUrd. Although measurement of modu- 
lation by comparing separate flasks of cells processed 
in parallel (with or without modulator) is the most 
direct experimental approach in vitro, this scheme 
would be impractical in oivo, where it is likely that 
only a single sample would be available from each 
treated subject. One way of circumventing this 
problem is to design the treatment protocol so that 
BrdUrd incorporated before addition of the 
modulator can be measured separately from that 
incorporated in the presence of the modulator,  in 
the same sample. Since our technique for measuring 
BrdUrd incorporation employs mass spectrometric 
detection, such a protocol is possible by using stable- 
isotope labeled BrdUrd.  
Figure 6 gives the results of an experiment in 
which HuTu80 and HT29 cells were exposed to 1/~M 
normotopic BrdUrd for one-sixth of a doubling time 
(3 or 4hr ,  respectively), at which point the cells 
were washed and incubated for the same time period 
with 1/~M isotopic BrdUrd + the indicated 
concentration of FUra.  As expected, the ratio of 
isotopic/normotopic BrdUrd was approximately 
doubled in HT29 cells, compared to controls, when 
concentrations of FUra  were 1 #M or higher. In 
HuTu80 cells this ratio was increased slightly at 
100/~M FUra  and essentially unchanged at lower 
FUra concentrations. The pattern of response to 
FdUrd was similar in that, in HT29 cells, modulation 
paralleled growth inhibition, whereas HuTu80 cells 
were essentially resistant to modulation even at high 
FdUrd concentrations. For both cell lines the 
absolute degree of modulation with FdUrd was 
slightly higher than with FUra. We also observed 
that the order of administration of the isotopic and 
normotopic forms of the drug made no detectable 
difference in the results obtained. 
DISCUSSION 
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Fig. 6. Measurement of modulation using stable-isotope 
labeled BrdUrd. HuTu80 or HT29 cells were exposed to 
1 #M normotopic BrdUrd for one-sixth of a doubling time 
(3 or 4hr, respectively), at which point the cells were 
washed and incubated for the same time period with 1 #M 
isotopic BrdUrd + the indicated concentration of FUra. 
Values are the means - SEM for three independent 
samples from a single, representative experiment. 
be enhanced substantially in HuTu80 cells, even by 
high fluoropyrimidine concentrations, was the most 
surprising result of this study. We had originally 
expected that modulation would be closely correlated 
with growth inhibition, but even though 10nM 
FdUrd/HT29 and 100nM FdUrd/HuTu80 both 
represent treatments which inhibit growth by 80%, 
incorporation of BrdUrd was almost tripled in HT29 
cells while it was increased by less than 50% in 
HuTu80 cells, compared to cells exposed to BrdUrd 
alone. Furthermore, while 10nM FdUrd caused 
about 50% growth inhibition in HuTu80 cells, it did 
not enhance BrdUrd incorporation at all. We were 
initially reluctant to conclude that such growth 
inhibitory treatments were truly ineffective at 
modulating BrdUrd utilization in HuTu80 cells, and 
we therefore considered some potential artifactual 
bases for these observations. 
Since BrdUrd can be depleted rapidly from 
medium [10, 11] and since the initial concentration 
of BrdUrd in the experiments shown in Fig. 2 was 
quite low (0.2 #M), we hypothesized that the lack 
of modulation might be explained by complete 
utilization of the extracellular BrdUrd. In that case 
all of the available BrdUrd would have been used 
without modulator present, providing no advantage 
upon the addition of modulator. However, measure- 
ment of BrdUrd levels in medium incubated with 
HuTu80 cells showed minimal disappearance of the 
Divergent patterns of BrdUrd incorporation in HCT cells 135 
drug, even over a 24-hr time period (not shown), 
indicating that depletion of BrdUrd is not the basis 
for lack of modulation. 
Another  possible artifact stems from the use of 
undialyzed serum in our initial experiments. We 
determined that the level of dThd in our medium 
was typically 0.1 to 0.2/~M, which is of the same 
order of magnitude as the C10 for BrdUrd in HuTu80 
cells. One could postulate that if this line were 
especially proficient at utilizing exogenous dThd (as 
is suggested by efficient incorporation of BrdUrd at 
low concentrations), then the extent of BrdUrd 
replacement might be more dependent on the 
exogenous BrdUrd :dThd  ratio than on the con- 
tribution of de n o v o  dThd nucleotides. The data in 
Fig. 3 argue against this interpretation, though, since 
they show that use of dialyzed serum and of a higher 
BrdUrd concentration (1/~M) did not increase 
modulation. Therefore, we have accepted the 
conclusion that the refractoriness of HuTu80 cells 
to fluoropyrimidine modulation is a function of the 
physiology of that cell line, rather than an 
experimental anomaly. 
One possible explanation for the failure of 
moderate FdUrd concentrations to modulate BrdUrd 
incorporation is by an alteration of the intracellular 
disposition (specifically the catabolism) of BrdUrd,  
by FdUrd treatment.  As mentioned earlier, BrdUrd 
depletion from the medium by HuTu80 cells was 
negligible. In contrast, incubation of BrdUrd- 
containing medium with HT29 cells resulted in 
extensive depletion of this nucleoside from the 
medium [11], accompanied by appearance in the 
medium of the corresponding base, bromouracil 
(data not shown). These data indicate that, while 
intracellular breakdown of BrdUrd by dThd 
phosphorylase is significant in HT29 cells, this 
process is minimal in HuTu80 cells, indicating that 
in the latter line dThd phosphorylase is either absent, 
inactive or saturated with endogenously produced 
dThd. If the failure of BrdUrd to be catabolized 
extensively is due to saturation of phosphorylase, 
then reduction of endogenous dThd synthesis could 
free some of this activity to degrade BrdUrd. It this 
scheme is correct, then one would expect to find 
substantial amounts of thymine in medium incubated 
with HuTu80 cells and it would also be predicted 
that FdUrd treatment should increase the conversion 
of BrdUrd to BrUra in this line. 
A second possibility is that the refractoriness of 
HuTu80 cells to modulation at high FP concentrations 
could be due to inhomogeneity of TS in this line. 
Since FUra  and FdUrd are equally ineffective 
modulators of BrdUrd in HuTu80 cells, it seems 
likely that inhibition of the common target enzyme 
for these drugs, TS, is the critical determinant rather 
than, for example, anabolism of either drug. 
However, total cellular content of TS appears not 
to be predictive of modulation since SW480 cells 
have about five times as much TS as HT29 cells, 
while the concentration-dependence of FUra- 
induced modulation is similar in these two lines [5]. 
Furthermore, TS concent of HuTu80 cells is only 
about twice that of the SW480 line and yet there is 
at least a 100-fold difference in the concentration of 
FUra needed to achieve the same degree of 
modulation in the two lines. 
While the bulk of HuTu80 TS seems to be 
inhibitable at concentrations only slightly higher 
than the other three cell lines, as suggested by the 
growth inhibition curves in Fig. 5, the failure of 
much higher concentrations of FdUrd to depress 
HuTu80 growth below 20% of control suggests that 
a subset of the TS of that cell line is refractory to 
inhibition. These findings are consistent with the 
concept that several of the enzymes involved in 
producing DNA precursors, including TS, are 
physically compartmentalized [12-14], and with 
some recent studies which specifically point to 
heterogeneity of intracellular TS activities [15, 16]. 
Alternatively, HuTu80 ceils may contain both wild 
type and variant forms of TS, as has been 
demonstrated in the HCT116 line [17, 18]. Both of 
these cases would predict the existence of a 
vulnerable subclass of TS which would bear the 
brunt of fluoropyrimidine treatment, and a privileged 
subclass of TS whose continued activity accounts for 
poor modulation of BrdUrd incorporation. 
Preferential inhibition of a vulnerable subclass of 
TS could also provide an explanation for the 
differences between modulation of BrdUrd and 
IdUrd in HuTu80 cells, if dehalogenation of IdUMP 
is significant in this line. Conversion of IdUMP to 
dUMP by TS has been demonstrated previously in 
a cell-free system [19] and in a number of cell lines 
[20, 21]. BrdUMP can also be dehalogenated, with 
an efficiency somewhat less than IdUMP, depending 
on the conditions used [19]. In both the HT29 and 
HuTu80 cell lines, modulation of IdUrd incorporation 
was significantly higher than that of BrdUrd. 
Although vulnerable TS may not contribute 
substantially to replicative DNA synthesis in HuTu80 
cells, its dehalogenation of BrdUMP and IdUMP 
could be significant. By this reasoning we would 
expect that modulation of IdUrd in HuTu80 cells 
is due almost exclusively to reduced dehalogenation 
by vulnerable TS, while in HT29 cells modulation is 
due to a combination of less dehalogenation and less 
production of de novo  thymidylate. 
Since it has been shown that dThd and its analogs 
can alter uptake of FdUrd by affecting dThd kinase 
activity [22], it is possible that co-incubation of 
BrdUrd with FdUrd may attenuate activation of the 
latter by dThd kinase. As indicated, earlier, however, 
the fact that both FdUrd and FUra are both poor 
modulators at high concentrations in HuTu80 ceils 
argues against an important role for anabolism in 
this system. 
Although the correct explanation for our obser- 
vations is not defined as yet, one thing that is clear 
from the data presented here is that there is likely 
to be a considerable degree of variability among 
human colorectal tumors with respect to both 
intrinsic ability to incorporate BrdUrd and ability to 
modulate that incorporation by FUra  or FdUrd.  
Furthermore, in view of the complexity of the models 
needed to rationalize our observations in vitro, 
prediction of the incorporation or modulation 
properties of a tumor in v ivo  will probably not be 
successful if based on measurements of individual 
pools or enzyme activities. While measurement of 
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incorporation with and without modulator is the 
most direct approach to characterizing the properties 
of a tumor in a given individual, one would need to 
take separate biopsy samples both before and after 
adding modulator to a BrdUrd infusion. In addition 
to the difficulties involved in obtaining serial 
specimens, normalization of incorporation values 
between the two samples would be quite problematic. 
In anticipation of this potential problem we have 
used the unique capability of our GC/MS assay to 
distinguish stable-isotope labeled BrdUrd, incor- 
porated in the absence of modulator, from 
normotopic BrdUrd, incorporated in the presence 
of the modulator. This approach permits assessment 
of modulation by a selected fluoropyrimidine 
treatment in a single specimen which would, in 
effect, act as its own control. As shown in Fig. 6, 
the double-label protocol gives results equivalent to 
measurement of modulation by comparison of 
samples processed in parallel. If both BrdUrd and 
IdUrd were used simultaneously, it might be possible 
to additionally obtain information about the extent 
of dehalogenation in a sample, by comparing the 
modulation of the two dThd analogs. Finally, if we 
are at some point able to satisfactorily reconcile the 
effects of fluoropyrimidines on modulation and 
growth inhibition, measurement of modulation using 
stable isotopes may be useful to predict the 
therapeutic efficacy of fluoropyrimidine treatments 
intended to be cytotoxic, rather than modulatory. 
In summary, we have shown that HCT cell lines 
vary considerably with regard to both their intrinsic 
ability to incorporate halogenated dThd analogs, as 
well as the effectiveness of fluoropyrimidines to 
modulate this incorporation. We speculate that the 
lack of an obvious relationship between reported TS 
content, growth inhibition and susceptibility to 
modulation may be due to differences among these 
lines in the intracellular distribution of this enzyme, 
or to the existence of a variant form of TS in the 
HuTu80 line. We propose that analysis of biopsy 
specimens following treatment with normotopic and 
stable-isotope labeled BrdUrd (and perhaps IdUrd) 
could be used to evaluate the sensitivity of individual 
tumors to modulation of analog incorporation by 
fluoropyrimidine treatment, and that this information 
would be useful not only for improving the use of 
these dThd analogs as radiosensitizers, but eventually 
for also predicting intrinsic sensitivity of individual 
tumors to fluoropyrimidine treatment. 
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